Form4insider filings, from the source

SEC Form 4 · accession 0001209191-16-132812

Orexigen Therapeutics, Inc. · OREXQ

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Michael Narachi
Officer — CEO & President · Director
Period of report
Jul 12, 2016
Accepted (ET)
Jul 14, 2016 · 8:46 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001382911

Table I — non-derivative securities

No Table I lines on this filing.

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock OptionF2,F1$4.02Jul 12, 2016A525,000A—Jul 11, 2026Common Stock525,000525,000D
Stock OptionF2,F3$4.02Jul 12, 2016A105,000A—Jul 11, 2026Common Stock105,000105,000D
Stock OptionF2,F1$15.00Jul 12, 2016A315,000A—Jul 11, 2026Common Stock315,000315,000D
Stock OptionF2,F3$15.00Jul 12, 2016A63,000A—Jul 11, 2026Common Stock63,00063,000D

Explanation of responses